Variable | DPQ + efavirenz N = 160 | DPQ + nevirapine N = 61 |
---|---|---|
Early treatment failure-no. (%) | 1 (0.6) | 0 |
Development of danger signs or severe malaria | 0 | 0 |
Parasitaemia on day 2 greater than day 0 | 0 | 0 |
Parasitemia on day 3 ≥ 25% of count on day 0 | 1 (0.6) | 0 |
Parasitemia on day 3 with axillary temperature ≥ 37.5 °C | 0 | 0 |
Late clinical failure-no. (%) | 0 | 0 |
Late parasitological failure-no. (%) | 7 (4.4) | 0 |
Recrudescence | 0 | 0 |
Reinfection | 6 (3.8) | 0 |
Indeterminate or sample unavailable | 1 (0.6) | 0 |
Adequate clinical and parasitolocal response rates by different scenarios | ||
Intention-to-treat analysis | ||
PCR-corrected cure rate-% (95% CI) | ||
Scenario 1a | 99.4 (95.6–99.9) | 100 |
Scenario 2b | 93.1 (88.0–96.2) | 100 |
PCR-uncorrected cure rate-% (95% CI) | ||
Scenario 1a | 95.6 (90.3–97.5) | 100 |
Scenario 2b | 89.4 (83.5–93.3) | 100 |
Scenario 3c | 89.9 (82.3–94.4) | 100 |
Scenario 4d | 89.8 (77.4–95.8) | 100 |
Per-protocol analysis | ||
Number of patients | 151 | 61 |
PCR-corrected cure rate-% (95% CI) | ||
Scenario 5e | 99.3 (95.4–99.9) | 100 |
Scenario 6f | 98.8 (95.1–99.7) | 100 |
PCR-uncorrected cure rate-% (95% CI) | ||
Scenario 5e | 95.3 (90.5–97.8) | 100 |
Scenario 6f | 94.7 (89.7–97.3) | 100 |